The Committee for Medicinal Products for Human Use (CHMP) of the EMA has given its approval for an additional production facility for Janssen's COVID-19 vaccine, increased production of Moderna's vaccine and the active substance of BioNTech/Pfizer's vaccine.
In relation to the additional production facility for the COVID-19 Janssen vaccine, developed by Janssen-Cilag International NV, a statement from the Ministry of Health said that the facility located in Marcy-l`Étoile, France, and operated by Sanofi Pasteur, will produce finished product.
This facility is expected to support the continued supply of Janssen's COVID-19 vaccine.
(CNA)
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
